Using imaging to predict how gastric cancer responds to targeted therapies
S1PR1-targeted PET imaging to predict and monitor response to HER2-targeting antibody-drug conjugates
This study is looking at how a special receptor can help doctors figure out which patients with HER2-positive gastric cancer will respond well to a new type of treatment called antibody-drug conjugates, using advanced imaging techniques to keep track of their progress.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10937435 on NIH RePORTER |
What this research studies
This research investigates how a specific receptor, S1PR1, can be used to predict and monitor the effectiveness of antibody-drug conjugates (ADCs) in treating HER2-positive gastric cancer. By employing advanced imaging techniques, the study aims to identify which patients will benefit from these therapies and who may develop resistance over time. The research will involve preclinical models to validate the imaging approach and correlate it with tumor characteristics. Patients may be monitored for their response to treatment using this innovative imaging method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-positive gastric cancer who are undergoing treatment with antibody-drug conjugates.
Not a fit: Patients with gastric cancer that is not classified as HER2-positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for gastric cancer patients, improving their chances of effective therapy.
How similar studies have performed: Other research has shown promising results using imaging techniques to assess treatment responses in cancer, suggesting that this approach may be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ribeiro Pereira, Patricia Manuela — Washington University
- Study coordinator: Ribeiro Pereira, Patricia Manuela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.